Paliperidone protects SK-N-SH cells against glutamate toxicity via Akt1/GSK3β signaling pathway

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 120-127

  Peng, Lei ^a   Zhang, Xingzhen ^a   Cui, Xianping ^b   Zhu, Dexiao ^a   Wu, Jintao ^a   Sun, Dong ^a   Yue, Qingwei ^a   Li, Zeyan ^a   Liu, Haili ^a   Li, Guibao ^a   zhang, Jing ^a   Xu, Hongyan ^a   Liu, Fuchen ^c   Qin, Chengkun ^b   Li, Mingfeng ^c   Sun, Jinhao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; Paliperidone; Protection; Schizophrenia; SK N SH

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; LACTATE DEHYDROGENASE; MESSENGER RNA; PALIPERIDONE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; ISOXAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PYRIMIDINE DERIVATIVE;

AKT1 GENE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GSK3BETA GENE; NERVE CELL CULTURE; NERVE CELL GROWTH; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL ENLARGEMENT; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TOXICITY; TUMOR CELL LINE;

ANTIPSYCHOTIC AGENTS; APOPTOSIS; CELL ENLARGEMENT; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; ENZYME INHIBITORS; GENE EXPRESSION; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; HUMANS; ISOXAZOLES; L-LACTATE DEHYDROGENASE; MORPHOLINES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84904113182     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.037     Document Type: Article

References (29)

1. Coyle J.T., Puttfarcken P. Oxidative stress: glutamate, and neurodegenerative disorders. Science 1993, 262:689-695.
2. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
3. Dickerson J., Sharp F.R. Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. Neuropsychopharmacology 2006, 31:1420-1430.
4. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
5. Fowler J.A., Bettinger T.L., Argo T.R. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin. Ther. 2008, 30(2):231-248.
6. Frangou S., Murray R.M. Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia. Br. Med. Bull. 1996, 52:587-596.
7. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
8. Gassó P., Mas S., Molina O., Bernardo M., Lafuente A., Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36:71-77.
9. Ghosh A., Greenberg M.E. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science 1995, 268:239-247.
10. Johnstone E.C., Frith C.D. Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients. Psychol. Med. 1996, 26:669-679.
11. Kandel E.S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253:210-229.
12. Kim N.R., Park S.W., Lee J.G., Kim Y.H. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:633-642.
13. Kishida K., Naka K.I. Amino acids and the spikes from the retinal ganglion cells. Science 1967, 156:648-650.
14. Koprivica V., Regardie K., Wolff C., Fernalld R., Murphy J.J., Kambayashi J., Kikuchi T., Jordan S. Aripiprazole protects cortical neurons from glutamate toxicity. Eur. J. Pharmacol. 2011, 651:73-76.
15. Koros E., Dorner-Ciossek C. The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect. 2007, 20:437-445.
16. Kozlovsky N., Shanon-Weickert C., Tomaskovic-Crook E., Kleinman J.E., Belmaker R.H., Agam G. Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J. Neural Transm. 2004, 111:1583-1592.
17. Kurosawa S., Hashimoto E., Ukai W., Toki S., Saito S., Saito T. Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J. Neural Transm. 2007, 114:1121-1128.
18. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., Aprille J.R., Dwyer D.S., Li X.M., Mahadik S.P., Duman R.S., Porter J.H., Modica-Napolitano J.S., Newton S.S., Csernansky J.G. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol. Rev. 2008, 60:358-403.
19. Lindenmayer J.P., Khan A., Iskander A., Abad M.T., Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J. Clin. Psychiatry 2007, 68:368-379.
20. Massana G., Salgad o-Pineda P., Junqué C., Pérez M., Baeza I., Pons A., Massana J., Navarro V., Blanch J., Morer A., Mercader J.M., Bernardo M. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol. 2005, 25:111-117.
21. Ono T., Hashimoto E., Ukai W., Ishii T., Saito T. The role of neural stem cells for in vitro models of schizophrenia: neuroprotection via Akt/ERK signal regulation. Schizophr. Res. 2010, 122:239-247.
22. Park S.W., Lee C.H., Lee J.G., Kim L.W., Shin B.S., Lee B.J., Kim Y.H. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci. Res. 2011, 69:283-290.
23. Qing H., Xu H., Wei Z., Gibson K., Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 2003, 17:1563-1570.
24. Scherk H., Falkai P. Effects of antipsychotics on brain structure. Curr. Opin. Psychiatry 2006, 19:145-150.
25. Schmidt A.J., Krieg J.C., Clement H.W., Hemmeter U.M., Schulz E., Vedder H., Heiser P. Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. J. Psychopharmacol. 2010, 24:349-354.
26. Wang Y., Qin Z. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 2010, 15:1382-1402.
27. Xiao Q., Wang C., Li J., Hou Q., Li J., Ma J., Wang W., Wang Z. Ginkgolide B protects hippocampal neurons from apoptosis induced by beta-amyloid 25-35 partly via up-regulation of brain-derived neurotrophic factor. Eur. J. Pharmacol. 2010, 647(1-3):48-54.
28. Yang M.C., Lung F.W. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology (Berl) 2011, 217:397-410.
29. Yulug B., Yildiz A., Hüdaoglu O., Kilic E., Cam E., Schäbitz W.R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res. Bull. 2006, 71:296-300.